Diagnostic impact of [18F]flutemetamol PET in early-onset dementia

Marissa D. Zwan*, Femke H. Bouwman, Elles Konijnenberg, Wiesje M. van der Flier, Adriaan A. Lammertsma, Frans R. J. Verhey, Pauline Aalten, Bart N. M. van Berckel, Philip Scheltens

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Article number2
Number of pages8
JournalAlzheimer's Research & Therapy
Volume9
DOIs
Publication statusPublished - 17 Jan 2017

Keywords

  • Alzheimer's disease
  • Dementia
  • Clinical practice
  • Diagnostic impact
  • Positron emission tomography
  • Imaging
  • Amyloid
  • PROGRESSIVE SUPRANUCLEAR PALSY
  • ALZHEIMERS-DISEASE
  • FRONTOTEMPORAL DEMENTIA
  • INTERNATIONAL WORKSHOP
  • NATIONAL INSTITUTE
  • DECISION-MAKING
  • CASE SERIES
  • BETA
  • CRITERIA
  • MANAGEMENT

Cite this

Zwan, M. D., Bouwman, F. H., Konijnenberg, E., van der Flier, W. M., Lammertsma, A. A., Verhey, F. R. J., Aalten, P., van Berckel, B. N. M., & Scheltens, P. (2017). Diagnostic impact of [18F]flutemetamol PET in early-onset dementia. Alzheimer's Research & Therapy, 9, [2]. https://doi.org/10.1186/s13195-016-0228-4